Adial Pharmaceuticals股价下跌,因季度亏损扩大

路透中文
Aug 17
BUZZ-<a href="https://laohu8.com/S/ADIL">Adial Pharmaceuticals</a>股价下跌,因季度亏损扩大

8月17日 - ** 药物研发公司Adial Pharmaceuticals(ADIL.O)的股价在盘前交易中下跌22.6%,至3.08美元

** 该公司第二季度每股亏损从上年同期的4.61美元扩大至11.25美元

** 净亏损从200万美元扩大至5200万美元,主要原因是与收购Azora Therapeutics相关的4620万美元非现金费用以及管理费用增加

** ADIL已完成对Azora的收购,由此获得了治疗溃疡性结肠炎的实验性药物AT177,并将业务重点转向炎症性疾病

** 公司计划于2027年上半年申请批准启动AT177的临床试验,预计早期临床试验将于2027年下半年开始

** 截至上一交易日收盘,ADIL今年以来累计下跌27.6%

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10